Baxter International Inc. (BAX) on Wednesday said China's State Food and Drug Administration or SFDA has approved ADVATE (Recombinant Human Coagulation Factor VIII for injection) for the control and prophylaxis of bleeding in individuals with hemophilia A.
Over 50,000 people in China are estimated to be living with hemophilia A. ADVATE is infused directly into the bloodstream. It works by temporarily raising the level of factor VIII in the bloodstream, allowing the body's blood clotting process to properly function. ADVATE is now approved in 54 countries worldwide.
''The approval of ADVATE in China marks an important milestone for Baxter and supports our ongoing commitment to treating individuals living with hemophilia,'' said Ludwig Hantson, Ph.D., president of Baxter's BioScience business.
For comments and feedback: editorial@rttnews.com